title: Oral delivery of heparin in combination with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate: pharmacological considerations.
authors.affiliation: Emisphere Technologies, Inc., Hawthorne, New York 10532, USA.
authors.forename: T M
authors.initials: TM
authors.lastname: Rivera
authors.forename: A
authors.initials: A
authors.lastname: Leone-Bay
authors.forename: D R
authors.initials: DR
authors.lastname: Paton
authors.forename: H R
authors.initials: HR
authors.lastname: Leipold
authors.forename: R A
authors.initials: RA
authors.lastname: Baughman
mesh_terms: D000284:Administration, Oral; D000818:Animals; D002210:Caprylates / Q000378:metabolism / Q000494:pharmacology*; D004338:Drug Combinations; D004386:Duodenum / Q000166:cytology / Q000187:drug effects; D005260:Female; D006493:Heparin / Q000008:administration & dosage / Q000493:pharmacokinetics*; D007082:Ileum / Q000166:cytology / Q000187:drug effects; D007408:Intestinal Absorption / Q000187:drug effects*; D007583:Jejunum / Q000166:cytology / Q000187:drug effects; D008252:Macaca fascicularis; D008297:Male; D010314:Partial Thromboplastin Time; D051381:Rats; D017207:Rats, Sprague-Dawley; D013270:Stomach / Q000166:cytology / Q000187:drug effects
chemical_list: D002210:Caprylates; D004338:Drug Combinations; C111140:N-(8-(2-hydroxybenzoyl)amino)caprylate; D006493:Heparin